The mir-135B-5p/ITGA2 signaling axis has been demonstrated to reduce the degree of EMT in gastric cancer chemotherapy trials by inhibiting the MAPK/ERK pathway, restoring gastric cancer cells’ chemotherapeutic sensitivity, and boosting mortality [65]. The gene discussed is ITGA2; the disease is gastric cancer.